Dashboard
Manage Tickers

CABA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

wells-fargo-maintains-overweight-on-cabaletta-bio-lowers-price-target-to-20
Wells Fargo Maintains Overweight on Cabale...
08/12/2024 17:41:50

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $...

evercore-isi-group-maintains-outperform-on-cabaletta-bio-lowers-price-target-to-15
Evercore ISI Group Maintains Outperform on...
08/12/2024 13:57:15

Evercore ISI Group analyst Gavin Clark-Gartner maintains Cabaletta Bio (NASDAQ:CABA) with a Outperform and lowers the price ...

hc-wainwright--co-maintains-buy-on-cabaletta-bio-lowers-price-target-to-25
HC Wainwright & Co. Maintains Buy on Cabal...
08/09/2024 21:00:21

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and lowers the price target fr...

cabaletta-bio-q2-2024-gaap-eps-056-misses-055-estimate-cash-cash-equivalents-and-short-term-investments-total-2032m-as-of-june-30-2024-expected-to-support-operations-into-the-first-half-of-2026
Cabaletta Bio Q2 2024 GAAP EPS $(0.56) Mis...
08/08/2024 12:30:16

cell-therapy-mostly-used-for-blood-cancer-shows-efficacy-in-autoimmune-diseases-as-well-but-there-are-challenges
Cell Therapy Mostly Used For Blood Cancer ...
07/19/2024 17:45:01

CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's...

why-kaival-brands-innovations-shares-are-trading-lower-by-47-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Kaival Brands Innovations Shares Are T...
06/21/2024 18:04:00

cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/21/2024 15:19:04

Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price tar...

asana-clover-health-investments-hertz-global-and-other-big-stocks-moving-higher-on-friday
Asana, Clover Health Investments, Hertz Gl...
06/21/2024 14:45:13

why-quantum-shares-are-trading-lower-by-45-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Quantum Shares Are Trading Lower By 45...
06/18/2024 17:39:53

why-ammo-shares-are-trading-lower-by-over-19-here-are-other-stocks-moving-in-fridays-mid-day-session
Why AMMO Shares Are Trading Lower By Over ...
06/14/2024 18:13:08

hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Caba...
06/14/2024 15:09:29

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

cabaletta-bio-announces-initial-clinical-data-from-phase-12-reset-myositis-and-reset-sle-trials-of-caba-201
Cabaletta Bio Announces Initial Clinical D...
06/14/2024 07:25:17

– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May ...

cabaletta-bio-13g-filing-shows-jennison-associates-llc-reports-111-passive-stake-in-the-co-as-of-may-31-2024
Cabaletta Bio 13G Filing Shows Jennison As...
06/06/2024 17:08:53

- SEC Filing

hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Caba...
05/24/2024 10:31:15

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on Caba...
05/16/2024 11:54:44

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $30 price target.

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

nextracker-posts-upbeat-earnings-joins-mondaycom-nu-holdings-and-other-big-stocks-moving-higher-on-wednesday
NEXTracker Posts Upbeat Earnings, Joins mo...
05/15/2024 14:21:59

cabaletta-bio-expects-that-its-cash-cash-equivalents-and-short-term-investments-of-2238m-as-of-march-31-2024-will-enable-it-to-fund-its-operating-plan-into-the-first-half-of-2026
Cabaletta Bio Expects That Its Cash, Cash ...
05/15/2024 11:12:43

cabaletta-bio-q1-2024-gaap-eps-051-misses-047-estimate
Cabaletta Bio Q1 2024 GAAP EPS $(0.51) Mis...
05/15/2024 11:11:42

cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:19:03

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION